Posts

Does Exercise Extend Life After a Prostate Cancer Diagnosis?

Image
Study Warns on Sedentary Behavior and Cancer Mortality | MedPage Today IPCSG Newsletter · Research Digest Does Exercise Extend Life After a Prostate Cancer Diagnosis? What randomized trials, large cohort studies, and the newest 2025–2026 research actually show — and where the evidence still runs out. IPCSG Newsletter | July 2026 BLUF — Bottom Line Up Front Physical activity after a prostate cancer diagnosis is consistently associated with lower rates of death from prostate cancer and from all causes in large observational cohorts — with the biggest apparent benefit tied to vigorous activity (roughly 3+ hours a week) and to men who have had surgery rather than radiation. But no completed randomized controlled trial has yet proven that exercise causes longer survival specifically in prostate cancer, the way one now has in colon cancer (the CHALLENGE trial, NEJM , June 2025). The definitive prostate trial, INTERVAL‑GAP4, could not recruit enough men a...
Post a Comment
Read more

Ac-225 Rosopatamab Tetraxetan (CONV01-α): CONVERGE-01 Interim Data Show Encouraging Activity After Lu-177-PSMA Therapy

Image
Ac-225 rosopatamab tetraxetan shows promising activity in Lu-PSMA–pretreated mCRPC | Urology Times Advanced Therapy Watch Informed Prostate Cancer Support Group Newsletter — Advanced & Metastatic Disease Series BLUF (Bottom Line Up Front):   At the 2026 ASCO Annual Meeting, Convergent Therapeutics reported interim Phase 2 results from Part 3 of the CONVERGE-01 trial testing Ac-225 rosopatamab tetraxetan (CONV01-α), an alpha-particle-emitting radioantibody, in men with metastatic castration-resistant prostate cancer (mCRPC) whose disease had already progressed after Lu-177-PSMA radioligand therapy — a population with no established standard of care. Among 35 treated patients, 40% of those evaluable for PSA response achieved a decline of 50% or more, with the best durability seen at the intended Phase 3 target dose (median radiographic progression-free survival of 8.41 months). Side effects were mostly blood-count related and manageable; there was no kidney toxi...
Post a Comment
Read more

Proton Therapy for Prostate Cancer: Key Takeaways

Image
Proton Therapy for Prostate Cancer: Key Takeaways Proton Therapy vs. IMRT for Prostate Cancer: What the Evidence, the Guidelines, and the Courts Say Now Informed Prostate Cancer Support Group (IPCSG) Newsletter — Patient Education Series — July 2026 BLUF (Bottom Line Up Front):   For most men with newly diagnosed low- or intermediate-risk localized prostate cancer, the best available randomized evidence — the phase III PARTIQoL trial — shows that proton beam therapy (PBT) and intensity-modulated radiation therapy (IMRT) produce statistically indistinguishable outcomes: roughly 93–94% five-year progression-free survival with both, and no meaningful difference in bowel, urinary, sexual, or hormonal side effects. Proton therapy typically costs substantially more, and insurers have been repeatedly sued — and have paid multimillion-dollar settlements — over improper denials, even though the treatments perform similarly for the average patient. The more promising, still-e...
Post a Comment
Read more

Recent Developments in Prostate Cancer Care

Image
Recent Developments in Prostate Cancer | MedPage Today A roundup of the practice-shaping trial data reported between February and June 2026 — ASCO GU, AUA, and the ASCO Annual Meeting — prepared for the IPCSG community BLUF — Bottom Line Up Front Six studies reported in the first half of 2026 collectively push treatment earlier and make it more precisely targeted to tumor biology. For men with high-risk localized disease, adding a year of apalutamide around surgery cut the risk of metastasis by 20% (PROTEUS). For men with hormone-sensitive metastatic disease carrying DNA-repair gene mutations, adding a PARP inhibitor (talazoparib) to enzalutamide cut progression risk by roughly half (TALAPRO-3). Darolutamide continues to distinguish itself on two fronts — real-world-comparable efficacy against a historical ADT-alone benchmark (ARASEC) and measurably less cognitive decline than enzalutamide (ARACOG). In first-line metastatic castration-resistant disease with BRCA1...
Post a Comment
Read more